
    
      This is a phase 2, randomized, double-blind, placebo-controlled study of the efficacy and
      safety of AR201 in a CODIT regimen in hen egg-allergic subjects aged 4 to 26 years,
      inclusive. The study will be conducted at approximately 30 sites in the United States.
    
  